Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài: " Pharmacogenetics, pharmacogenomics and airway disease Ian P Hall. | Available online http content 3 1 10 Review Pharmacogenetics pharmacogenomics and airway disease Ian P Hall Queens Medical Centre Nottingham UK Correspondence Professor Ian P. Hall Division of Therapeutics C Floor South Block Queens Medical Centre Nottingham UK. Tel 44 115 970 9985 fax 44 115 942 2232 e-mail Received 8 May 2001 Revisions requested 6 June 2001 Revisions received 23 October 2001 Accepted 23 October 2001 Published 26 November 2001 Respir Res 2002 3 10 2002 BioMed Central Ltd Print ISSN 1465-9921 Online ISSN 1465-993X Abstract The availability of a draft sequence for the human genome will revolutionise research into airway disease. This review deals with two of the most important areas impinging on the treatment of patients pharmacogenetics and pharmacogenomics. Considerable inter-individual variation exists at the DNA level in targets for medication and variability in response to treatment may in part be determined by this genetic variation. Increased knowledge about the human genome might also permit the identification of novel therapeutic targets by expression profiling at the RNA genomics or protein proteomics level. This review describes recent advances in pharmacogenetics and pharmacogenomics with regard to airway disease. Keywords asthma chronic obstructive pulmonary disease expression profiling pharmacogenetics pharmacogenomics proteomics single-nucleotide polymorphism Introduction The recent publication of two draft sequences for the human genome together with rapidly increasing knowledge of the extent of genetic variability between individuals available from resources such as the SNP Consortium in which SNP stands for single-nucleotide polymorphism has major implications for the study of respiratory disease. Genetic variability between individuals in drug-metabolising enzymes or in the primary targets for drugs might account in part for inter-individual variability in treatment response. .
